Tolerability and adverse events experienced by women with ovarian cancer treated with intravenous or intraperitoneal chemotherapy plus veliparib and bevacizumab based on BRCA status

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2020-10, Vol.159, p.15-16
Main Authors: Gillen, J., Miller, A., Moore, K.N., Bell-McGuinn, K.M., Schilder, R., Walker, J.L., Brady, W.E., O'Cearbhaill, R.E., Guntupalli, S.R., Armstrong, D.K., Hagemann, A.R., Gray, H.J., Duska, L.R., Mathews, C.A., Chen, A., O'Malley, D.M., Gordon, S.W., Fracasso, P.M., Aghajanian, C.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2020.06.029